SCHEMBL6480923

SCHEMBL6480923

CCCS(=O)(=O)NCC(C)Oc1ccc(-c2ccccc2C(F)(F)F)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRIA4 P48058 5/20 0.51
PPARA Q07869 2/20 0.46
PPARG P37231 1/20 0.46
HSD11B1 P28845 1/20 0.41
FFAR4 Q5NUL3 1/20 0.41
LGMN Q99538 1/20 0.36
CNR2 P34972 1/20 0.36
NR1D1 P20393 3/20 0.35
ADAMTS4 O75173 1/20 0.35
MMP13 P45452 1/20 0.35
SLC13A5 Q86YT5 1/20 0.34
MMP1 P03956 1/20 0.34
MMP2 P08253 1/20 0.34
MMP9 P14780 1/20 0.34
MMP14 P50281 1/20 0.34
ADAM17 P78536 1/20 0.34
MTNR1A P48039 1/20 0.34
MTNR1B P49286 1/20 0.34
SRD5A2 P31213 1/20 0.34
MME P08473 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6473890 0.85 GRIA4 (0.69) GRIA4PPARAPPARGFFAR4MTNR1A
SCHEMBL6480921 0.85 PPARG (0.48) GRIA4PPARAPPARGFFAR4LGMN
SCHEMBL6480940 0.84 GRIA4 (0.52) GRIA4PPARAPPARGMTNR1AMTNR1B
SCHEMBL6480970 0.83 GRIA4 (0.51) GRIA4PPARANR1D1MTNR1AMTNR1B
SCHEMBL6474227 0.83 KIF11 (0.46) GRIA4ADAMTS4MMP13MMP1MMP2
SCHEMBL6475297 0.82 GRIA4 (0.48) GRIA4PPARAPPARGMMP13MTNR1A
SCHEMBL6482324 0.82 GRIA4 (0.46) GRIA4MMP13MMP1MMP2MMP9
SCHEMBL6481768 0.81 GRIA4 (0.49) GRIA4PPARAPPARGMTNR1AMTNR1B
SCHEMBL6475469 0.80 PLAU (0.43) GRIA4NR1D1ADAMTS4MMP13
SCHEMBL6475311 0.79 GRIA4 (0.47) GRIA4ADAMTS4MTNR1AMTNR1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1265857-A1 SULFONAMIDE DERIVATIVES ELI LILLY AND COMPANY (US) 2002-12-18 EP claimed
WO-2001068592-A1 SULFONAMIDE DERIVATIVES ELI LILLY AND COMPANY (US) 2001-09-20 WO claimed
US-6911476-B2 Sulfonamide derivatives ELI LILLY AND COMPANY (US) 2005-06-28 US disclosed
US-20030225266-A1 Sulfonamide derivatives ELI LILLY AND COMPANY 2003-12-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030225266-A1 Sulfonamide derivatives GRIN2A, GRM2, GRIA2 GRIA4 6/4885PPARA 1066/4885PPARG 828/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.